Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYB004 Safety and Immunogenicity in Older Adults
NCT06335849Phase 1Active, not recruiting
- Sponsor
- Patronus Biotech
- Start
- Mar 2024
- Primary completion
- Sep 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LYB004 in herpes zoster (HZ) (3 arms), sponsored by Patronus Biotech. Primary endpoints: Reactogenicity of LYB004 vaccine, Safety and Reactogenicity of LYB004 vaccine and 3 more. Started Mar 2024; status: active, not recruiting.
02
Drugs
LYB004
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT06335849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06335849.